Mayne Pharma Group Limited

ASX MYX.AX

Mayne Pharma Group Limited Gross Profit for the year ending June 30, 2024: USD 145.71 M

Mayne Pharma Group Limited Gross Profit is USD 145.71 M for the year ending June 30, 2024, a 715.79% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.
  • Mayne Pharma Group Limited Gross Profit for the year ending June 30, 2023 was USD 17.86 M, a 8.99% change year over year.
  • Mayne Pharma Group Limited Gross Profit for the year ending June 30, 2022 was USD 16.39 M, a -82.79% change year over year.
  • Mayne Pharma Group Limited Gross Profit for the year ending June 30, 2021 was USD 95.24 M, a -2.11% change year over year.
  • Mayne Pharma Group Limited Gross Profit for the year ending June 30, 2020 was USD 97.29 M, a -33.72% change year over year.
Key data
Date Gross Profit Operating Income EBIT EBITDA
Market news
Loading...
ASX: MYX.AX

Mayne Pharma Group Limited

CEO Mr. Shawn Patrick O'Brien B.Sc
IPO Date June 29, 2007
Location Australia
Headquarters 1538 Main North Road
Employees 850
Sector Health Care
Industries
Description

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. The company operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Similar companies

MSB.AX

Mesoblast Limited

USD 1.58

-2.06%

GEM.AX

G8 Education Limited

USD 0.79

2.65%

NAN.AX

Nanosonics Limited

USD 2.01

-0.68%

StockViz Staff

January 15, 2025

Any question? Send us an email